Picture of Sinopharm logo

1099 — Sinopharm News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedLarge CapContrarian

HK-listed Sinopharm rises on regulatory approval for Merck's anti-COVID pill

** Shares of China's pharmaceutical products distributor
Sinopharm Group Co. Ltd  1099.HK  rise as much as 3.3% to
HK$20.50
    ** Shares on course for their biggest daily pct rise since
Dec. 12, if gains hold
    ** Shanghai-based company says China's National Medical
Products Administration had given the emergency conditional
approval to Molnupiravir for the treatment of adult patients
with mild to moderate COVID-19 infection  urn:newsml:reuters.com:*:nB9N33401I
    ** Company says its controlling shareholder, China National
Pharmaceutical Group, had in September 2022 been granted
distribution and exclusive import right of Molnupiravir capsule,
developed by Merck  MRK.N  and Ridgeback Biotherapeutics LP, in
mainland China
    ** Says its unit Sinopharm Group Distribution Co Ltd is
responsible for the import and distribution of Molnupiravir, the
world's first approved oral anti-COVID medication, in the
mainland during the term of the agreement
    ** The Hang Seng Commerce & Industry Index  .HSNC  rises
1.9%, healthcare index  .HSCIH  surges 2.6% and the Hang Seng
Index  .HSI  climbs 1.6%
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))

Recent news on Sinopharm

See all news